These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 22983922)

  • 1. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.
    Chow HY; Jubb AM; Koch JN; Jaffer ZM; Stepanova D; Campbell DA; Duron SG; O'Farrell M; Cai KQ; Klein-Szanto AJ; Gutkind JS; Hoeflich KP; Chernoff J
    Cancer Res; 2012 Nov; 72(22):5966-75. PubMed ID: 22983922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
    Song P; Song B; Liu J; Wang X; Nan X; Wang J
    Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
    Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
    Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
    Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP
    Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
    Vandal G; Geiling B; Dankort D
    PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways.
    Huynh N; Liu KH; Baldwin GS; He H
    Biochim Biophys Acta; 2010 Sep; 1803(9):1106-13. PubMed ID: 20595063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
    Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
    Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathway.
    Lin G; Tang Z; Ye YB; Chen Q
    Oncol Rep; 2012 May; 27(5):1527-34. PubMed ID: 22327383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
    Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
    Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
    Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
    Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.